... We Welcome You To The Resverlogix HUB On AGORACOM!

**Apabetalone (RVX-208) Currently Being Tested in a Phase 3 BETonMACE Cardiovascular Outcomes Trial (now fully enrolled) and Will Soon Begin Phase 2 Kidney Dialysis and Fabry Disease Trials**


BREAKING: Good Life Networks Inc. increases second quarter revenue year over year by 123% to $3,435,835

  • Q2 revenue increased 123% to $3,435,835 from same quarter last year
  • Reported net income of $252,712, compared to a net loss of $353,632 in the same quarter last year
  • “Our year over year revenue growth for the second quarter was exceptional and further supports our projected revenue and earnings objectives for the full fiscal year,” said Jesse Dylan, GLN President and CEO

Glnlogo black 11

Hub On AGORACOM / Read Release


Message: A longtime holder

We have been down this road before, a few weeks before an AGM, the management decide it is time to release a few snippets of information to the retail share holders and then all is good again, I still want to know what the issues are with not announcing the opening of Betonmace sites in the US. Why weren't they ready, after all Mr M has been courting the FDA for quite some time. Yes I get the funds may not have available but wouldn't you think the FDA would want to know how they plan to proceed before they approve the Betonmace trial. Why no information on the mentioned changes to the FA from 125 events to some where above, or the expansion of the trial enrollments to include US patients. Some other posters have had issues with other points but to me this is the most important issue of all and should not get lost in the noise of the lead up to the AGM. Any prosective investor would want to know this. Coldnewfie not so cold in Mexico.


New Message
Please login to post a reply